Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Filing tables
Filing exhibits
- 10-K Annual report
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.2 EX-10.2
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.28 EX-10.28
- 10.29 EX-10.29
- 10.30 EX-10.30
- 10.7 EX-10.7
- 10.8 EX-10.8
- 21.1 EX-21.1
- 23.1 EX-23.1
- 31.1 EX-31.1
- 31.2 EX-31.2
- 32.1 EX-32.1
- Download Excel data file
- View Excel data file
Related press release
Associated SBBP transcripts
SBBP similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-222818, 333-215532) of our report dated March 12, 2018, with respect to the consolidated financial statements of Strongbridge Biopharma plc included in this Annual Report (Form 10-K) for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Philadelphia, Pennsylvania
March 12, 2018